Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Berman

Showing results (451-460 of 459) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 459 results.
Journal of Virology|February 2, 2018
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among VaccineesNicole L Yates, Allan C deCamp, Bette T Korber, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 28, 2007
NeuroAIDS, drug abuse, and inflammation: building collaborative research activitiesJoan W Berman, Monica J Carson, Linda Chang, et al.
JCI Insight|November 8, 2022
In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cellsKim Anthony-Gonda, Alex Ray, Hang Su, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Pageof 46

Showing results (451-460 of 459) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 459 results.
Journal of Virology|February 2, 2018
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among VaccineesNicole L Yates, Allan C deCamp, Bette T Korber, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 28, 2007
NeuroAIDS, drug abuse, and inflammation: building collaborative research activitiesJoan W Berman, Monica J Carson, Linda Chang, et al.
JCI Insight|November 8, 2022
In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cellsKim Anthony-Gonda, Alex Ray, Hang Su, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Pageof 46